Introduction
Secondary AH has a prevalence of 3-5%. The treatment of the cause can cure AH or improve BP control. Chart 1 shows the situations in which secondary causes of AH should be investigated.
Chronic kidney disease
Chronic kidney disease is defined by a GFR < 60 mL/min or abnormal findings in urinalysis and/or kidney morphology for 3 months. 1 As CKD advances, AH increases progressively, affecting 90% of stage 5 patients. 2 All patients with AH should have plasma creatinine measured, their GFR calculated and urinalysis performed to screen for CKD. 3 (GR: I; LE: A). Additional investigation includes renal US for all. 3 Other exams (albuminuria, CT, MRI) can be necessary. Kidney biopsy is indisputably indicated in the presence of rapid decline in glomerular filtration or proteinuria > 3.5 g/g of urine creatinine. 4 Arterial hypertension accelerates the progression of CKD 5 and BP reduction attenuates CKD course. 6 The treatment goals and most indicated medications for BP control in patients with CKD are described in Chapter 8. For CKD patients on dialysis, BP reduction decreases mortality, 7 and loop DIUs are indicated in the presence of residual renal function, as well as ultrafiltration, in selected cases. 8 
Renovascular hypertension
Renovascular hypertension (RVAH) is secondary to partial or total, uni-or bilateral stenosis of the renal artery or of one of its branches, triggered and maintained by renal tissue ischemia. The RVAH prevalence is 5% of hypertensive patients. 9 Its major cause is atherosclerosis (90%), followed by renal artery fibromuscular dysplasia, 10 Takayasu's arteritis being the less frequent. 9 Regardless of its cause, it is an important determinant of CV morbidity and mortality. 10 The diagnosis and assessment of the extent of involvement with TOD are essential for the choice of treatment. A costeffective investigation requires proper selection of candidates, and anatomical and functional assessment of the stenosis, in addition to methods to correct the anatomical and functional defect.
11 Charts 2 and 3 12-14 list the main steps. The indication for the therapeutic option should consider the etiology and clinical conditions associated with renal artery stenosis, such as AH, ischemic nephropathy and accelerated CVD. Evidence of benefit of the percutaneous or surgical mechanical treatment is restricted to situations, such as progressive renal function loss, APE and difficulty to control BP, that cause irreversible TOD. 15 Regarding patients with RVAH due to fibromuscular dysplasia, 82-100% of them have BP control, and 10%, restenosis. 11 (GR: IIa; LE: B). Regarding atherosclerotic RVAH without complications, three randomized studies have shown no benefit of stent implantation as compared to optimized clinical treatment in BP control, kidney disease progression, and occurrence of clinical events and mortality. [16] [17] [18] For patients with atherosclerotic renal artery stenosis and controlled BP with clinical treatment, without heart complications and stable kidney function for 6-12 months, the mechanical intervention is not recommended, clinical treatment being the first option. (GR: II; LE: B). 
Obstructive sleep apnea-hypopnea syndrome
Obstructive sleep apnea-hypopnea syndrome is characterized by recurring upper airway obstructions during sleep, causing reductions in intrathoracic pressure, intermittent hypoxia and sleep fragmentation. 19 There is evidence that OSAHS is related to the development of AH regardless of obesity. 20, 21 The prevalence of OSAHS in patients with AH is 30-56%, 22, 23 reaching 64-83% in those with resistant AH (RAH). 24, 25 OSAHS contributes to TOD 26 and acceleration of atherosclerosis in hypertensives. 27 The risk factors for OSAHS are age, male sex, obesity and MS. The Berlin questionnaire 28 can be used to screen for OSAHS, 23 but does not seem useful in patients with RAH. 29 Changes in the physiological BP decrease during nocturnal sleep can indicate the presence of OSAHS. 30 Polysomnography or home respiratory polygraphy confirms the diagnosis with the finding of at least five episodes of apnea and/or hypopnea per hour of sleep (apnea-hypopnea index -AHI), and an AHI ≥15 events/hour seems to have a higher impact on AH. 31 The treatment of choice for moderate or severe OSAHS is the use of continuous positive airway pressure (CPAP) during sleep. 31 Meta-analyses have shown a small effect of CPAP in reducing BP, but they have limitations because they included studies on individuals with normal BP and controlled hypertensives. [32] [33] [34] Most randomized studies [35] [36] [37] [38] on patients with OSAHS and RAH have shown more significant reductions in BP than those of patients with non-resistant AH. Body weight loss in combination with CPAP has resulted in greater BP reduction than each isolated intervention in obese individuals with OSAHS. 39 Mandibular advancement with mobile orthodontic devices for mild to moderate OSAHS can 34 but further studies are necessary. 34 Although several antihypertensive classes have been tested, 40 there is no definitive conclusion about the best drug for hypertensives with OSAHS. 40, 41 Primary hyperaldosteronism Primary hyperaldosteronism (PHA) is a clinical condition characterized by excessive, inappropriate and autonomous production of aldosterone 42 (Aldo), caused by bilateral adrenal hyperplasia or unilateral Aldo producing adenoma (APA), and, more rarely, unilateral adrenal hyperplasia, adrenal carcinoma or genetic origin (monogenic or chimeric gene). The prevalence of PHA in hypertensives is 3-22%, being higher in stage 3 and/or resistant hypertensives. 43 Primary hyperaldosteronism is suspected when AH is associated with: spontaneous or DIU-induced hypokalemia; adrenal incidentaloma; RAH; family history of AH or CbVD before the age of 40 years; and MS. The prevalence of hypokalemia in PHA is 9-37%. Laboratory tests do not require suspension of antihypertensive agents, except for spironolactone for 4-6 weeks. 43 Suppressed plasma renin activity (PRA) and Aldo > 15 ng/dL, with an Aldo/PRA ratio > 30, indicate the diagnosis of PHA. Confirmatory testing is recommended when Aldo > 15 ng/dL and < 25 ng/dL, with an Aldo/PRA ratio > 30 and < 100. The furosemide and captopril tests have higher diagnostic accuracy than the saline infusion test. 44 In the furosemide upright test, the patient should remain lying down for at least 30 minutes, then receive 40 mg of furosemide (IV), and renin should be measured after 2 hours of walking. The test is positive if PRA < 2 ng/ mL/h. In the captopril challenge test, 50 mg of captopril are administered orally after the patient remained seated or in the upright position for at least 1 hour. Renin and Aldo should be measured at the times 0, 60 and 120 minutes. The test is positive if there is no drop > 30% in plasma Aldo or if it remains > 12 ng/dL. In the saline infusion test, 2 liters of 0.9% saline are administered (IV) in 4 hours. The Aldo measurement will be ≥ 5 ng/dL.
For APA or hyperplasia to be detected, thin-sliced CT or MRI of the adrenal glands is indicated. 43 Catheterization of the adrenal veins is indicated when, on CT, the adrenal glands are normal, have bilateral abnormalities (thickening or micronodules) or a unilateral lesion in patients > 40 years. 44 The dexamethasone suppression test is indicated to investigate PHA suppressible with glucocorticoid in patients with PHA and AH beginning before the age of 40 years. 44 Laparoscopic surgery is indicated in APA, 43 preferably with previous treatment with spironolactone up to 3-4 weeks. Clinical treatment of hyperplasia requires spironolactone, 50-300 mg/day, if well tolerated. 45 Cure of AH with surgery is observed in 35-60% of the patients.
42,45
Pheochromocytomas Pheochromocytomas (PHEO) are tumors of chromaffin cells of the sympathetic adrenomedullary axis that produce catecholamines. 46 Of PHEOs, 10% to 15% are extraadrenal (paragangliomas), 10% are bilateral, and 10% are malignant. 47 Familial forms have the dominant autosomal trait or are part of syndromes with known gene mutations. 47 Presence of persistent or paroxysmal AH (50%), paroxysmal headache, excessive sweating and palpitations (classic triad) 46 is indicative of the disease, and concomitance of the classic triad with HC has sensitivity of 89% and specificity of 67% for the PHEO diagnosis. 46 Laboratory diagnosis is based on the measurement of catecholamines and their metabolites in blood and urine. Free plasma metanephrine has the highest sensitivity and specificity, 48 but because of its higher cost, urine metanephrine isolated or associated with plasma catecholamines is indicated in cases of high likelihood. 48 The measurement of urine vanillylmandelic acid has good specificity, but the lowest sensitivity of all methods, being indicated only when the other tests are not available. 48 If the diagnosis is not certain, clonidine suppression test is indicated in hypertensives, and glucagon stimulation test, in individuals with normal BP levels.
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Figure 2 -Flowchart for primary hyperaldosteronism screening, diagnostic confirmation and treatment. *The furosemide and captopril tests have higher diagnostic accuracy than the saline infusion test.
The imaging tests to locate adrenal tumors are CT and MRI, with sensitivity of 89% and 98%, respectively. 49 The MRI is superior to identify paragangliomas. MIBG whole body scan is useful in extraadrenal, bilateral PHEOs, and metastases and relapses. 50 Octreoscan, bone scan and positron-emission CT can be indicated when the localizing exams cited are negative or when investigating malignancy. 51 The preferential treatment is surgery, whose preoperative preparation should include alpha1-blockers (doxazosin or prazosin) and appropriate hydration for at least 2 weeks before surgery. 52 The chronic pharmacological treatment includes alpha1-blockers, BBs (only after beginning alpha1-blockers, in the presence of symptomatic tachycardia), CCBs, ACEIs and central action agonists. 52 The paroxysmal HC of PHEO is a HE, and should be treated with SNP or injectable phentolamine and volume replacement, if necessary. 46 Total and early removal of the neoplasm usually determines total remission of symptoms and cure of AH. 47, 49 For malignant PHEOs with unresectable metastases, the following are indicated: chemotherapy, embolization, radiotherapy, and, if possible, ablation with MIBG-131. 47 Clinical, biochemical and radiological follow-up of the patients is essential to detect recurrences or metastases, in the malignant form, and other tumor in familial syndromes.
Other endocrine causes
Hypothyroidism
In hypothyroidism, AH occurs in 20% of hypothyroid patients. 53 The diagnosis is established by finding high TSH levels and gradual decrease in free T4. The most common clinical findings are weight gain, hair loss and muscle weakness. The treatment is initiated with thyroid hormone replacement, 53 and, if AH persists, antihypertensive drugs are indicated. (GR: II; LE: C).
Hyperthyroidism
In hyperthyroidism, AH is a frequent finding in hyperthyroidism, and the clinical presentation mimics hyperadrenergic findings. The main symptoms are palpitation, tremor, fatigue, increased sensitivity to heat, hyperactivity, weight loss and emotional lability. 54 The most important signs are exophthalmos, hyperthermia, hyperreflexia and humid skin. 54 The diagnosis is confirmed by low TSH levels and high free T4 levels. The treatment usually normalizes BP. Beta-blockers are the first choice to control the adrenergic symptoms. (GR: IIb; LE: C).
Hyperparathyroidism
In hyperparathyroidism, there is excessive secretion of parathormone (PTH) by the parathyroid glands, with consequent hypercalcemia and hypophosphatemia. 55 It can be caused by an adenoma or hyperplasia of the parathyroid glands. Secondary hyperparathyroidism results from a situation that induces hypocalcemia, CKD being the major cause. The most common symptoms are depression, thirst, polyuria, renal lithiasis, osteoporosis, lethargy, muscle weakness, muscle spasms, and renal function reduction. Arterial hypertension is present in up to 75% of the patients, and can be resistant. 43 The diagnosis is established with plasma calcium and PTH measurement. Surgical correction of hyperparathyroidism can cure or reduce BP in hypertensives. 56 
Cushing's syndrome
Cushing's syndrome (CS) is a disorder caused by excessive cortisol levels associated with a deficiency in the control mechanism of the hypothalamus-hypophysis-adrenal axis and of the cortisol secretion circadian rhythm. 57 It can result from adrenal tumors with autonomous cortisol production (benign or malignant adenoma), adrenal hyperplasia, excessive adrenocorticotropin (ACTH) production, or ectopic tumor. 57 The prevalence of AH in CS is 80% in adults and 47% in children. 57 The major signs and symptoms are decreased libido, central obesity, moon face, striae, muscle weakness, and hirsutism. 58 The confirmatory tests are: 24-hour urine free cortisol; nocturnal salivary cortisol; dexamethasone suppression test; dexamethasone combined with corticotropin-releasing hormone test; and ACTH measurement. 58 Pituitary MRI shows an adenoma in 35% to 60% of patients. 58 Surgical removal of the tumor can cure AH, but 30% of the patients maintain SAH, and 25%, DAH. 59 The AH duration before surgery correlates with postoperative AH persistence. 59 Thiazides and furosemide should be avoided, because they can worsen hypokalemia, ACEIs and ARBs being recommended.
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Acromegaly
Acromegaly is usually caused by a pituitary adenoma that secrets growth hormone (GH) and insulin-like growth factor type 1 (IGF-1). It manifests as progressive excessive growth of the hands, feet and facial bones, increased interdental spacing, mandibular prognathism, macroglossia, excessive sweating, and respiratory, CV, metabolic-endocrine and skeletal-muscle changes. 60 In acromegaly, AH has a 35% prevalence, and contributes to increase the disease's morbidity and mortality. Acromegalic cardiomyopathy contributes to raise BP, and can be aggravated by the coexistence of AH. The treatment of acromegaly reduces BP in parallel with GH reduction.
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Coarctation of the aorta
Coarctation of the aorta is the aortic constriction close to the ductus arteriosus or ligament, found mainly in children and young adults. Clinical suspicion is based on symptoms (epistaxis, headache and weakness of the legs on exertion or manifestations of HF, angina, aorta dissection or intracerebral hemorrhage) and physical exam (upper limb AH, with SBP at least 10 mm Hg greater in the brachial artery than in the popliteal artery; pulse absence or decrease in lower limbs; interscapular and thoracic systolic murmur). [61] [62] [63] The imaging exams include: chest X ray (thoracic aorta with pre-and post-stenosis dilations, costal corrosion); echocardiogram (posterior protrusion, expanded isthmus, transverse aortic arch, and high velocity continuous jet in the coarctation site); angiography with MRI (details of coarctation and intercostal vessels). The MRI is the best method for assessment and post-intervention follow-up in young individuals, and does not require preoperative angiography. Invasive angiography is indicated when other imaging methods do not provide visualization of the coarctation, and to older individuals who can have CAD. The definition of significant coarctation requires pre-and post-coarctation pressure gradient > 20 mm Hg. 62 Patients who do not undergo surgery have a higher incidence of CV events. The treatment is always interventional: endovascular procedure (younger individuals or children) or surgery (hypoplasia of the aortic arch and/or need for coarctation resection). The BP response to interventional treatment depends on the duration of AH prior to surgery and the patient's age. The cure of AH occurs in up to 50% of patients, but AH can reoccur later, especially if the intervention is performed at advanced age. The drugs of choice for both the preoperative period and residual AH after surgery are BBs and ACEIs.
Drug-induced AH
Chart 4 shows the medicines and licit and illicit drugs related to AH development or worsening. 
